EDWARD ZAWADZKI: Open Payments
NPI 1346467305 · JUPITER, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$506 in 26 payments from 13 companies in 2025. Trend: 2023 $155 · 2024 $554 · 2025 $506
Food & beverage: $506
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 4 | $88 |
| Otsuka America Pharmaceutical, Inc. | 4 | $81 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| ABBVIE INC. | 2 | $49 |
| Vanda Pharmaceuticals Inc. | 2 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Indivior Inc. | 2 | $31 |
| Neuronetics, Inc. | 1 | $22 |
| Braeburn Inc. | 1 | $21 |
Products named: REXULTI, INGREZZA, TRINTELLIX, VRAYLAR, FANAPT, CAPLYTA, AUSTEDO XR, SUBLOCADE.
Industry payments across FL — which companies pay providers there.
